UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program

ESMO open, 2022-12, Vol.7 (6), p.100634, Article 100634

2022

Volltextzugriff (PDF)

597P Endometrial carcinoma and mismatch repair deficiency: Clinical association and universal screening for Lynch syndrome

Annals of oncology, 2022-09, Vol.33, p.S819

2022

Volltextzugriff (PDF)

1469P Efficacy and safety of pembrolizumab/axitinib combination in metastatic renal cell carcinoma (mRCC): A multicentric prospective analysis (ProPAXI study)

Annals of oncology, 2022-09, Vol.33, p.S1218

2022

Volltextzugriff (PDF)

1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study

Annals of oncology, 2022-09, Vol.33, p.S1221-S1222

2022

Volltextzugriff (PDF)

802TiP Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: The multicentric retrospective Meet-URO 18 study

Annals of oncology, 2020-09, Vol.31, p.S607-S608

2020

Volltextzugriff (PDF)

Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair/microsatellite unstable metastatic colorectal cancer

ESMO Gastrointestinal Oncology, 2024-09, Vol.5, Article 100069

2024

Volltextzugriff (PDF)

Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients

Breast Cancer: Basic and Clinical Research, 2020, Vol.14, p.117822342095417

2020

Volltextzugriff (PDF)

Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence

Cancers, 2021-11, Vol.13 (21), p.5517

2021

Volltextzugriff (PDF)

Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer

Journal of oncology pharmacy practice, 2023-10, Vol.29 (7), p.1748-1753

2023

Volltextzugriff (PDF)

The controversial abscopal effect: A single-center experience about the combination of stereotactic radiotherapy with pembrolizumab in patients with metastatic dMMR/MSI-H colorectal cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2608-2608

2023

Volltextzugriff (PDF)

Rare anti-VEGFR therapy-induced toxicity and long-term response to immunotherapy in a rare non-clear cell renal cell carcinoma patient

Anti-cancer drugs, 2022-01, Vol.33 (1), p.e724

2022

Volltextzugriff (PDF)

Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study

Frontiers in oncology, 2024-02, Vol.14, p.1307635-1307635

2024

Volltextzugriff (PDF)

Early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.349-349

2022

Volltextzugriff (PDF)

Gender-specific aspects related to type of fertility preservation strategies and access to fertility care

ESMO open, 2020-01, Vol.5 (Suppl 4), p.e000771-e000771, Article e000771

2020

Volltextzugriff (PDF)

Correlation of the immune tumor microenvironment (I-TME) with gene expression profiles as prognostic and predictive factors in patients (pts) with metastatic renal carcinoma (mRCC) treated with immunotherapy (Meet-URO 18 I-TME study)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS753-TPS753

2023

Volltextzugriff (PDF)

Prognostic stratification by the Meet-URO score in a real-world elderly population of patients (pts) with metastatic renal cell carcinoma (mRCC) receiving cabozantinib: A subanalysis of the prospective ZEBRA study (Meet-URO 9)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.637-637

2023

Volltextzugriff (PDF)

Feasibility of multiple immunoexpression assay for immune tumor micrornvironment (I-TME) on matched metastatic and primary renal cell carcinoma (RCC) for patient prognostication and predictiveness to immunotherapy (preliminary analyses of the Meet URO 18 study)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e16545-e16545

2021

Volltextzugriff (PDF)

Moving trastuzumab emtansine (T-DM1) to the early setting of breast cancer treatment

Annals of palliative medicine, 2020-03, Vol.9 (2), p.512-516

2020

Volltextzugriff (PDF)

Immunotherapy retreatment: case report, review of the literature and proposal for the definition of different scenarios

Immunotherapy, 2021-06, Vol.13 (8), p.645-652

2021

Volltextzugriff (PDF)

412 Pembrolizumab in metastatic cancer patients with microsatellite instability: subgroup analysis on endometrial cancer patients, results from a single center study

International journal of gynecological cancer, 2023-09, Vol.33 (Suppl 3), p.A158-A158

2023

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Immunotherapy
(11)
Oncology
(11)
Humans
(8)
Immune Checkpoint Inhibitor
(6)
Metastasis
(6)
Renal Cell Carcinoma
(6)
Nivolumab
(4)
Patients
(4)
Prognosis
(4)
Carcinoma, Renal Cell - Drug Therapy
(3)
Cd56
(3)
Immune Checkpoint Inhibitors
(3)
Male
(3)
Medical Prognosis
(3)
Metastases
(3)
Pd-L1
(3)
Prognostic
(3)
Prospective Studies
(3)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

7 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program

597P Endometrial carcinoma and mismatch repair deficiency: Clinical association and universal screening for Lynch syndrome

1469P Efficacy and safety of pembrolizumab/axitinib combination in metastatic renal cell carcinoma (mRCC): A multicentric prospective analysis (ProPAXI study)

1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study

802TiP Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: The multicentric retrospective Meet-URO 18 study

Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair/microsatellite unstable metastatic colorectal cancer

Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients

Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence

The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study

Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer

The controversial abscopal effect: A single-center experience about the combination of stereotactic radiotherapy with pembrolizumab in patients with metastatic dMMR/MSI-H colorectal cancer

Rare anti-VEGFR therapy-induced toxicity and long-term response to immunotherapy in a rare non-clear cell renal cell carcinoma patient

Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study

Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study

Early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations

Gender-specific aspects related to type of fertility preservation strategies and access to fertility care

Correlation of the immune tumor microenvironment (I-TME) with gene expression profiles as prognostic and predictive factors in patients (pts) with metastatic renal carcinoma (mRCC) treated with immunotherapy (Meet-URO 18 I-TME study)

Prognostic stratification by the Meet-URO score in a real-world elderly population of patients (pts) with metastatic renal cell carcinoma (mRCC) receiving cabozantinib: A subanalysis of the prospective ZEBRA study (Meet-URO 9)

Feasibility of multiple immunoexpression assay for immune tumor micrornvironment (I-TME) on matched metastatic and primary renal cell carcinoma (RCC) for patient prognostication and predictiveness to immunotherapy (preliminary analyses of the Meet URO 18 study)

Moving trastuzumab emtansine (T-DM1) to the early setting of breast cancer treatment

Immunotherapy retreatment: case report, review of the literature and proposal for the definition of different scenarios

412 Pembrolizumab in metastatic cancer patients with microsatellite instability: subgroup analysis on endometrial cancer patients, results from a single center study

Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)

Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)

Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)

Suchergebnisse filtern